Biomx Inc

Biomx Inc

BiomX Inc (PHGE) is a very small‑cap stock (market capitalisation about $15.56M) that may appeal to investors who monitor early‑stage or niche biotechnology opportunities. Small market capitalisation often means low liquidity and higher price volatility; share moves can be large on limited news. Important factors for such companies typically include R&D progress, regulatory milestones, cash runway and financing plans — any of which can materially affect value. Because information can be sparse and outcomes binary, thorough due diligence is essential: read company filings, recent presentations and trusted analyst commentary. This summary is for general educational purposes only and is not investment advice; values can fall as well as rise. Consider your tolerance for speculative, micro‑cap biotech risk and whether this fits a diversified portfolio before acting. If unsure, consult a regulated financial adviser for personalised suitability guidance.

Stock Performance Snapshot

Buy

Analyst Rating

Analysts are optimistic about Biomx's stock, recommending a buy with a target price of $22.

Above Average

Financial Health

Biomx Inc shows solid cash flow and book value, indicating a strong financial position.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Baskets Featuring PHGE

Microbiome Modulators

Microbiome Modulators

Discover a carefully selected group of innovative biotechnology companies leveraging the untapped power of the body's microbiome. These pioneering firms are creating revolutionary therapies that target the root causes of disease by rebalancing our internal microbial ecosystems.

Published: June 17, 2025

Explore Basket

Why You’ll Want to Watch This Stock

📈

Small‑Cap Dynamics

Micro‑cap status can mean big price moves on limited news; useful for active research but expect higher volatility and lower liquidity.

Binary Catalysts Matter

Clinical or regulatory announcements (if applicable) and financing rounds can sharply move the stock—though outcomes are uncertain and can be negative.

🌍

Do your research

Review filings, cash runway and management commentary; consider independent analysis and whether this risk profile suits your diversification needs.

Why invest with Nemo?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Frequently asked questions